Trajectories and risk factors of fatigue following colorectal cancer diagnosis
- PMID: 37700526
- PMCID: PMC10815933
- DOI: 10.1111/codi.16746
Trajectories and risk factors of fatigue following colorectal cancer diagnosis
Abstract
Aim: This study sought to identify groups of colorectal cancer patients based upon trajectories of fatigue and examine how demographic, clinical and behavioural risk factors differentiate these groups.
Method: Patients were from six cancer centres in the United States and Germany. Fatigue was measured using the fatigue subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at five time points (baseline/enrolment and 3, 6, 12 and 24 months after diagnosis). Piecewise growth mixture models identified latent trajectories of fatigue. Logistic regression models examined differences in demographic, clinical and behavioural characteristics between fatigue trajectory groups.
Results: Among 1615 participants (57% men, 86% non-Hispanic White, mean age 61 ± 13 years at diagnosis), three distinct groups were identified. In the high fatigue group (36%), fatigue significantly increased in the first 6 months after diagnosis and then showed statistically and clinically significant improvement from 6 to 24 months (P values < 0.01). Throughout the study period, average fatigue met or exceeded cutoffs for clinical significance. In the moderate (34%) and low (30%) fatigue groups, fatigue levels remained below or near population norms across the study period. Patients who were diagnosed with Stage II-IV disease and/or current smokers were more likely to be in the high fatigue than in the moderate fatigue group (P values < 0.05).
Conclusion: A large proportion of colorectal cancer patients experienced sustained fatigue after initiation of cancer treatment. Patients with high fatigue at the time of diagnosis may benefit from early supportive care.
Keywords: colorectal cancer; fatigue; growth mixture models; longitudinal study design; multicentre consortium; quality of life.
© 2023 Association of Coloproctology of Great Britain and Ireland.
Conflict of interest statement
Conflict of Interest
H.S.L.J. reports consulting to SBR Bioscience and grant funding from Kite Pharma. B.D.G reports fees unrelated to this work from Sure Med Compliance and Elly Health. K.M. reports consultant to Reimagine Care. All other authors declare no conflicts of interest.
Figures

Similar articles
-
Symptom trajectories in breast cancer survivors: growth mixture analysis of patient-reported pain, fatigue, insomnia, breast and arm symptoms.Acta Oncol. 2021 Dec;60(12):1659-1667. doi: 10.1080/0284186X.2021.1981550. Epub 2021 Sep 28. Acta Oncol. 2021. PMID: 34582319
-
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1. Lancet Oncol. 2021. PMID: 33812497 Clinical Trial.
-
The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.Med J Aust. 2019 Jun;210(11):499-506. doi: 10.5694/mja2.50207. Epub 2019 Jun 2. Med J Aust. 2019. PMID: 31155722
-
Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.BMC Cancer. 2021 Jan 27;21(1):99. doi: 10.1186/s12885-021-07793-w. BMC Cancer. 2021. PMID: 33499819 Free PMC article.
-
Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer.Cochrane Database Syst Rev. 2020 May 3;5(5):CD012864. doi: 10.1002/14651858.CD012864.pub2. Cochrane Database Syst Rev. 2020. PMID: 32361988 Free PMC article.
Cited by
-
Prevalence of cancer-related fatigue syndrome and its association with sociodemographic and clinical characteristics in adult patients with colorectal cancer: a cross-sectional study.Support Care Cancer. 2024 Nov 22;32(12):814. doi: 10.1007/s00520-024-09010-3. Support Care Cancer. 2024. PMID: 39572423
-
Distinct Trajectories of Fatigue Among Families with Post-Intensive Care Syndrome.Int J Gen Med. 2025 Jun 12;18:3093-3103. doi: 10.2147/IJGM.S513018. eCollection 2025. Int J Gen Med. 2025. PMID: 40529347 Free PMC article.
-
Network analysis of fatigue symptoms in Chinese patients with advanced cancer.Asia Pac J Oncol Nurs. 2024 Dec 14;12:100641. doi: 10.1016/j.apjon.2024.100641. eCollection 2025 Dec. Asia Pac J Oncol Nurs. 2024. PMID: 39886056 Free PMC article.
-
Fatigue trajectory and its associated factors in patients after pituitary adenoma surgery: a longitudinal study.Support Care Cancer. 2025 Jul 19;33(8):702. doi: 10.1007/s00520-025-09745-7. Support Care Cancer. 2025. PMID: 40682661
-
Functional quality of life among newly diagnosed young adult colorectal cancer survivors compared to older adults: results from the ColoCare Study.Support Care Cancer. 2024 Apr 19;32(5):298. doi: 10.1007/s00520-024-08511-5. Support Care Cancer. 2024. PMID: 38639810 Free PMC article.
References
-
- Couwenberg AM, Burbach JPM, van Grevenstein WMU, Smits AB, Consten ECJ, Schiphorst AHW, et al. Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis. Clin Colorectal Cancer. 2018;17(3):e499–e512. - PubMed
-
- Wu HS, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs. 2015;38(1):E29–54. - PubMed
-
- Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12 Suppl 1:4–10. - PubMed
MeSH terms
Grants and funding
- P30-CA076292/CA/NCI NIH HHS/United States
- KL2TR00-2539/NH/NIH HHS/United States
- R01CA207371/CA/NCI NIH HHS/United States
- R03 CA270473/CA/NCI NIH HHS/United States
- R01 CA189184/CA/NCI NIH HHS/United States
- U01 CA206110/CA/NCI NIH HHS/United States
- 1A1 R01 CA189184/CA/NCI NIH HHS/United States
- T32 HG008962/NH/NIH HHS/United States
- R01 CA254108/CA/NCI NIH HHS/United States
- R2 U01 CA206110/CA/NCI NIH HHS/United States
- R01NR018762/NR/NINR NIH HHS/United States
- T32CA009168/CA/NCI NIH HHS/United States
- KL2 TR002539/TR/NCATS NIH HHS/United States
- R01CA211705/CA/NCI NIH HHS/United States
- P30 CA076292/CA/NCI NIH HHS/United States
- T32 HG008962/HG/NHGRI NIH HHS/United States
- T32 CA009168/CA/NCI NIH HHS/United States
- R01 NR018762/NR/NINR NIH HHS/United States
- R01 CA207371/CA/NCI NIH HHS/United States
- R01CA254108/CA/NCI NIH HHS/United States
- R01 CA211705/CA/NCI NIH HHS/United States
- R03CA270473/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous